Losartan Impurity 34 | CAS 158365-99-2 - Request Quote
Losartan Impurity 34
| SZ CAT No: | SZ-L028072 |
| CAS No | 158365-99-2 |
| Mol.F. | C7H11ClN2 |
| Mol.Wt. | 158.6 |
| Inv. Status | Synthesis on demand |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Losartan Impurity 34 is chemically 2-Butyl-5-chloro-1H-imidazole. Losartan Impurity 34 is supplied with detailed characterization data compliant with regulatory guideline. Losartan Impurity 34 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Losartan.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
Buy 158365-99-2
Purchase 158365-99-2
Order 158365-99-2
Enquire 158365-99-2
price of 158365-99-2
158365-99-2 Supplier
158365-99-2 Manufacturer
158365-99-2 Exporter
buy high quality Losartan Impurity 34
Purchase Losartan Impurity 34
Losartan Impurity 34 suppliers
Losartan Impurity 34 manufacturers
Losartan Impurity 34 price
Order Losartan Impurity 34
Enquire Losartan Impurity 34
Losartan Impurity 34 cost
Losartan Impurity 34 Supplier
Losartan Impurity 34 Distributor
Losartan Impurity 34 for Method Validation
Losartan Reference Standard
Losartan Impurity 34 for ANDA Filing
Losartan Impurity 34 for Forced Degradation Studies
Losartan Impurity 34 Identification Standards
Losartan Impurity 34 for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.


